Founded in 2020, Marginum is revolutionising oncological surgery.
With the developed tissue detection technology for surgery, Marginum aims to make a real impact by helping millions of patients and surgical professionals around the globe.
Accurate identification of tumours and distinguishing them from healthy tissues during cancer surgery is a critical challenge surgeons face. With an ageing population and the projected 55 % increase in global cancer incidence by 2040, there will be over 20 million cancer patients each year in need of surgery.
Marginum’s minimally invasive tissue monitoring technology empowers surgeons with precise information about the presence and extent of tumour tissue without compromising pre-existent surgical workflow. The patent-pending solution aims to enable surgeons to perform more accurate and targeted resections, reducing tumour recurrence and the need for reoperations while improving patient safety and surgical outcomes.
“Almaral invests in early-stage biotech and life science companies with technologies that can significantly enhance healthcare professionals' ability to deliver services with improved efficiency, quality, or significantly reduced costs, without compromising the quality of care. Marginum enables fundamental changes in the surgical market and contributes to solving a global health issue.”
– Dr. Maria Severina
Founder & CEO, Almaral
“Nostetta Ventures invests in early-stage companies with groundbreaking innovations and exceptional teams within North Savo region. Marginum’s industry-shaping technology has its origins in the University of Eastern Finland, and the team excels in surgical technology, clinical research, and rapid advancement of the company’s technology.”
– Noora Tuikka
CEO, Nostetta Ventures
“Redstone is a European venture capital firm following selected investment strategies. Redstone’s North Karelia Growth Fund invests in companies that build upon regional strengths in technology and life sciences. Marginum’s promising technology enables positive societal change with safer and more accurate surgery.”
– Kaj Hagros
Managing Partner, Redstone Nordics
"Marginum is developing the next-generation fluorescence-based optical tissue monitoring technology to improve surgical performance and cost-effectiveness. There is an urgent need to decrease healthcare costs and the number of reoperations and complications.
The Marginum™ tissue monitoring solution enables safe and efficient tumour detection from surgical suction waste. The surgeon will be notified in real-time if tumour traces are present in the resected tissue. This minimally invasive approach – easily integrated into the current surgical workflow – aims for precise detection of tumour cells and minimal damage to healthy tissues.
Our dedicated multidisciplinary team works closely with clinical, academic and industrial leaders to ensure our solutions’ seamless clinical compatibility according to clinicians’ preferences."
Samu Lehtonen, MD BSc
CEO & Co-Founder
We aim to achieve this by developing a groundbreaking fluorescence-based tissue detection system that enables efficient and safe monitoring of tissues during cancer surgery.
Unlike any other solution, Marginum allows precise quantitative detection of tumours from surgical suction waste without compromising workflow. With our technology we hope to fulfil our vision to radically improve surgical outcomes and patient welfare, welcoming a data-driven shift in surgical approach.
Keep up with the insights into Marginum’s pioneering advancements and transformative investment opportunities.
10.11.2023 | Marginum News
Almaral, Nostetta Ventures, and Redstone led the investment into Finnish medical technology company Marginum, coupled with Business Finland R&D loan.
22.3.2023 | Marginum News
Marginum Ltd has initiated its first-in-human clinical trials with the aspirate tissue monitor at the Kuopio University Hospital.
21.2.2023 | Tahko Ski Lift Pitch
Tahko Ski Lift Pitch winner Marginum is pioneering optic tissue monitoring with groundbreaking innovation borne from multidisciplinary UEF research.
10.10.2022 | Kuopio Chamber of Commerce
Marginum joins Kuopio Chamber of Commerce and the Finnish Startup Community after winning Tahko Ski Lift Pitch 2022.
4.10.2022 | University of Eastern Finland
Marginum has been nominated by University of Eastern Finland (UEF) to participate at Stage Two competition in Berlin.
13.9.2022 | Kuopio Health
Marginum joined Kuopio Health to further connect with research institutions and other member companies in the medical technology industry.